| [1] |
|
| [2] |
|
| [3] |
Kip AE, Schellens JHM, Beijnen JH, et al. Clinical pharmacokinetics of systemically administered antileishmanial drugs [J]. Clin Pharmacokinet, 2018, 57(2): 151-176. DOI: 10.1007/s40262-017-0570-0.
|
| [4] |
|
| [5] |
|
| [6] |
Sundar S, Singh A. Recent developments and future prospects in the treatment of visceral Leishmaniasis[J]. Ther Adv Infect Dis, 2016, 3(3-4): 98-109. DOI: 10.1177/2049936116646063.
|
| [7] |
World Health Organization. Control of the Leishmaniases [J]. World Health Organ Tech Rep Ser, 2010, (949): 1-186.
|
| [8] |
Aronson N, Herwaldt BL, Libman M, et al. Diagnosis and treatment of Leishmaniasis: clinical practice guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH) [J]. Clin Infect Dis, 2016, 63(12): 1539-1557. DOI: 10.1177/2049936116646063.
|
| [9] |
张富南，张丽萍. 四川省黑热病复发和死亡原因分析[J]. 预防医学情报杂志，2010, 26(12): 961-965.
|
| [10] |
|
| [11] |
Sundar S, Chakravarty J. An update on pharmacotherapy for Leishmaniasis [J]. Exp Opin Pharmacother, 2015, 16(2): 237-252. DOI: 10.1517/14656566.2015.973850.
|
| [12] |
Hasnain MG, Nath P, Maruf S, et al. Amphotericin B deoxycholate for relapse visceral Leishmaniasis in Bangladesh: a cross-sectional study [J]. BMC Res Notes, 2018, 11(1): 918. DOI: 10.1186/s13104-018-4036-8.
|
| [13] |
Sundar S, Agarwal D. Visceral Leishmaniasis-optimum treatment options in children [J]. Pediatr Infect Dis J, 2018, 37(5): 492-494. DOI: 10.1097/INF.0000000000001885.
|
| [14] |
Sundar S, Singh A, Rai M, et al. Single-dose indigenous liposomal amphotericin B in the treatment of Indian visceral Leishmaniasis: a phase 2 study [J]. Am J Trop Med Hyg, 2015, 92(3): 513-517. DOI: 10.4269/ajtmh.14-0259.
|
| [15] |
Pandey K, Pal B, Siddiqui NA, et al. Efficacy and safety of liposomal amphotericin B for visceral Leishmaniasis in children and adolescents at a Tertiary Care Center in Bihar, India[J]. Am J Trop Med Hyg, 2017, 97(5): 1498-1502. DOI: 10.4269/ajtmh.17-0094.
|
| [16] |
Mondal D, Alvar J, Hasnain MG, et al. Efficacy and safety of single-dose liposomal amphotericin B for visceral Leishmaniasis in a rural public hospital in Bangladesh: a feasibility study [J]. Lancet Glob Health, 2014, 2(1): e51-e57. DOI: 10.1016/S2214-109X(13)70118-9.
|
| [17] |
Burza S, Sinha PK, Mahajan R, et al. Five-year field results and long-term effectiveness of 20 mg/kg liposomal amphotericin B (ambisome) for visceral Leishmaniasis in Bihar, India [J]. PLoS Negl Trop Dis, 2014, 8(1): e2603. DOI: 10.1371/journal.pntd.0002603.
|
| [18] |
Krepis P, Argyri I, Krepi A, et al. Short-course regimens of liposomal amphotericin B for the treatment of mediterranean visceral Leishmaniasis in children: an 11-year retrospective study at a Tertiary Care Center [J]. Pediatr Infect Dis J, 2017, 36(9): 849-854. DOI: 10.1097/INF.0000000000001602.
|
| [19] |
Jamil KM, Haque R, Rahman R, et al. Effectiveness study of paromomycin IM injection (PMIM) for the treatment of visceral Leishmaniasis (VL) in Bangladesh [J]. PLoS Negl Trop Dis， 2015, 9(10): e0004118. DOI: 10.1371/journal.pntd.0004118.
|
| [20] |
Hailu A, Musa A, Wasunna M, et al. Geographical variation in the response of visceral Leishmaniasis to paromomycin in East Africa: a multicentre, open-label, randomized trial [J]. PLoS Negl Trop Dis, 2010, 4(10): e709. DOI: 10.1371/journal.pntd.0000709.
|
| [21] |
Hendrickx S, Mondelaers A, Eberhardt E, et al. In vivo selection of paromomycin and miltefosine resistance in Leishmania donovani and L. infantum in a Syrian hamster model [J]. Antimicrob Agents Chemother, 2015, 59(8): 4714-4718. DOI: 10.1128/AAC.00707-15.
|
| [22] |
Mbui J, Olobo J, Omollo R, et al. Pharmacokinetics, safety, and efficacy of an allometric miltefosine regimen for the treatment of visceral Leishmaniasis in Eastern African children: an open-label, phase Ⅱ clinical trial [J]. Clin Infect Dis, 2019, 68(9): 1530-1538. DOI: 10.1093/cid/ciy747.
|
| [23] |
Diro E, Ritmeijer K, Boelaert M, et al. Use of pentamidine as secondary prophylaxis to prevent visceral Leishmaniasis relapse in HIV infected patients, the first twelve months of a prospective cohort study [J]. PLoS Negl Trop Dis, 2015, 9(10): e0004087. DOI: 10.1371/journal.pntd.0004087.
|
| [24] |
van Griensven J, Diro E. Visceral Leishmaniasis: recent advances in diagnostics and treatment regimens [J]. Infect Dis Clin North Am, 2019, 33(1): 79-99. DOI: 10.1016/j.idc.2018.10.005.
|
| [25] |
Sundar S, Sinha PK, Rai M, et al. Comparison of short-course multidrug treatment with standard therapy for visceral Leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial [J]. Lancet, 2011, 377(9764): 477-486. DOI: 10.1016/S0140-6736(10)62050-8.
|
| [26] |
Rahman R, Goyal V, Haque R, et al. Safety and efficacy of short course combination regimens with AmBisome, miltefosine and paromomycin for the treatment of visceral Leishmaniasis (VL) in Bangladesh [J]. PLoS Negl Trop Dis, 2017, 11(5): e0005635. DOI: 10.1371/journal.pntd.0005635.
|
| [27] |
Kimutai R, Musa AM, Njoroge S, et al. Safety and effectiveness of sodium stibogluconate and paromomycin combination for the treatment of visceral Leishmaniasis in Eastern Africa: results from a pharmacovigilance programme [J]. Clin Drug Investig, 2017, 37(3): 259-272. DOI: 10.1007/s40261-016-0481-0.
|
| [28] |
Diro E, Lynen L, Mohammed R, et al. High parasitological failure rate of visceral Leishmaniasis to sodium stibogluconate among HIV co-infected adults in Ethiopia[J]. PLoS Negl Trop Dis, 2014, 8(5): e2875. DOI: 10.1371/journal.pntd.0002875.
|
| [29] |
Monge-Maillo B, López-Vélez R. Treatment options for visceral Leishmaniasis and HIV coinfection[J]. AIDS Rev, 2016，18(1): 32-43. PMID:26936761.
|
| [30] |
Cipriano P, Miranda AC, Antunes I, et al. Visceral Leishmaniasis in HIV-infected patients: the challenge of relapse and treatment failure [J]. Acta Med Port, 2017, 30(6): 443-448. DOI: 10.20344/amp.8291.
|
| [31] |
Diro E, Lynen L, Ritmeijer K, et al. Visceral Leishmaniasis and HIV coinfection in East Africa[J]. PLoS Negl Trop Dis, 2014, 8(6): e2869. DOI： 10.1371/journal.pntd.0002869.
|
| [32] |
Mahajan R, Das P, Isaakidis P, et al. Combination treatment for visceral Leishmaniasis patients coinfected with human immunodeficiency virus in India [J]. Clin Infect Dis, 2015, 61(8): 1255-1262. DOI: 10.1016/j.ijid.2016.02.166.
|
| [33] |
Abongomera C, Diro E, de Lima Pereira A, et al. The initial effectiveness of liposomal amphotericin B (ambisome) and miltefosine combination for treatment of visceral Leishmaniasis in HIV co-infected patients in Ethiopia: a retrospective cohort study[J]. PLoS Negl Trop Dis, 2018, 12(5): e0006527. DOI： 10.1371/journal.pntd.0006527.
|
| [34] |
Diro E, Blesson S, Edwards T, et al. A randomized trial of ambisome monotherapy and ambisome and miltefosine combination to treat visceral Leishmaniasis in HIV co-infected patients in Ethiopia [J]. PLoS Negl Trop Dis, 2019, 13(1): e0006988. DOI: 10.1371/journal.pntd.0006988.
|
| [35] |
Diro E, Edwards T, Ritmeijer K, et al. Long term outcomes and prognostics of visceral Leishmaniasis in HIV infected patients with use of pentamidine as secondary prophylaxis based on CD4 level: a prospective cohort study in Ethiopia [J]. PLoS Negl Trop Dis, 2019, 13(2): e0007132. DOI: 10.1371/journal.pntd.0007132.
|